###begin article-title 0
###xml 102 107 <span type="species:ncbi:9606">human</span>
The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 187 193 187 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 381 387 381 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 244 249 <span type="species:ncbi:9606">human</span>
###xml 401 406 <span type="species:ncbi:9606">human</span>
ISG15 is an ubiquitin-like molecule that is strongly upregulated by type I interferons as a primary response to diverse microbial and cellular stress stimuli. However, alterations in the ISG15 signalling pathway have also been found in several human tumour entities. To the best of our knowledge, in the current study we present for the first time a systematic characterisation of ISG15 expression in human breast cancer and normal breast tissue both at the mRNA and protein level.
###end p 3
###begin title 4
Method
###end title 4
###begin p 5
###xml 119 125 119 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 167 169 167 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 203 204 203 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 213 219 213 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 547 548 547 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 576 582 576 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
Using semiquantitative real-time PCR, cDNA dot-blot hybridisation and immunohistochemistry, we systematically analysed ISG15 expression in invasive breast carcinomas (n = 910) and normal breast tissues (n = 135). ISG15 protein expression was analysed in two independent cohorts on tissue microarrays; in an initial evaluation set of 179 breast carcinomas and 51 normal breast tissues; and in a second large validation set of 646 breast carcinomas and 10 normal breast tissues. In addition, a collection of benign and malignant mammary cell lines (n = 9) were investigated for ISG15 expression.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 138 140 138 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 162 164 162 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 186 188 186 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 256 262 256 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
ISG15 was overexpressed in breast carcinoma cells compared with normal breast tissue, both at the RNA and protein level. Recurrence-free (p = 0.030), event-free (p = 0.001) and overall (p = 0.001) survival analyses showed a significant correlation between ISG15 overexpression and unfavourable prognosis.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 11 17 11 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 121 129 <span type="species:ncbi:9606">patients</span>
###xml 178 183 <span type="species:ncbi:9606">human</span>
Therefore, ISG15 may represent a novel breast tumour marker with prognostic significance and may be helpful in selecting patients for and predicting response to the treatment of human breast cancer.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15</italic>
###xml 165 171 165 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 297 300 297 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jak</italic>
###xml 327 328 327 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 329 330 329 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 350 356 350 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 424 430 424 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 487 488 487 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 505 511 505 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 760 766 760 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 861 862 861 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 891 892 891 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 967 973 967 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 1021 1022 1021 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
The interferon-stimulated gene 15 kDa (ISG15) is an interferon-inducible ubiquitin-like protein. In addition to being stimulated by type I interferon, expression of ISG15 is greatly induced by viral or bacterial infection through the Janus kinase/signal transducer and activator of transcription (Jak/STAT) signalling pathway [1-3]. After induction, ISG15 is secreted by monocytes, B- and T-lymphocytes and fibroblasts. The ISG15 protein is made up of tandem ubiquitin homology domains [4]. Within cells, ISG15 is covalently conjugated with cellular proteins in an enzymatic pathway (so called ISGylation) comprised of the activating E1, conjugating E2 and ligating E3 enzymes, which are similar to those used by ubiquitin (ubiquitylation). The conjugation of ISG15 with protein substrates provides a tag that either marks the labelled protein for degradation [5] or modulates its function [6]. Importantly, protein ISGylation is a reversible process, and removal of ISG15 molecules is mediated by de-ISGylating enzymes [7].
###end p 11
###begin p 12
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 195 201 195 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 232 233 232 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 568 569 568 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
Multiple target proteins of ISG15 have recently been identified, some of which have been implicated in the regulation of immune responses. However, the biological consequences of modification by ISG15 need to be determined further [8]. Interestingly, protein ubiquitylation has been shown to be of fundamental importance in the regulation of both the innate and adaptive immune systems, with roles in the control of immune tolerance, the differentiation of T-cells and the intracellular signal transduction induced by antigen, cytokines or toll-like receptor ligands [9].
###end p 12
###begin p 13
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 71 77 71 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 216 222 216 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 307 309 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 402 408 402 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 453 459 453 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 501 506 501 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 555 561 555 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 671 677 671 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 678 680 678 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 681 683 681 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 709 715 709 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 776 778 776 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
So far, little is known about the function of ISG15 in carcinogenesis. ISG15 is a post-translational protein modifier and also a secreted cytokine. Each of these roles has been implicated in carcinogenesis, although ISG15 was recently thought to function as an oncogene as well as a tumour-suppressor gene [10]. Enhanced ISGylation was observed in response to cancer chemotherapeutics, suggesting that ISG15 has a tumour-suppressing function. Moreover, ISG15 is a target of the tumour-suppressor gene TP53 [11]. In contrast, deregulated overexpression of ISG15 and enhanced ISGylation were positively correlated with cancerogenesis underlining the oncogenic potential of ISG15 [12-14]. As a secreted protein, ISG15 has been shown to primarily modulate immune cell activation [15].
###end p 13
###begin p 14
###xml 12 18 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 212 218 212 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 346 352 346 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 476 482 476 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 575 581 575 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 673 675 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 370 375 <span type="species:ncbi:9606">human</span>
Some of the ISG15 target proteins also have functions in the cell nucleus including chromatin remodelling and polymerase II transcription [16]. Interestingly, in bladder cancer immunohistochemistry revealed that ISG15 was located predominantly in the nuclei of cancer cells which were associated with an advanced tumour stage [12]. Surprisingly, ISG15 overexpression in human bladder cancer has not been found to be associated with a general inflammatory response even though ISG15 was expected to be stimulated by interferon primarily in an inflammatory process. Therefore, ISG15 expression in bladder cancer suggests that it is specifically associated with tumour cells [12].
###end p 14
###begin p 15
###xml 18 24 18 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 217 223 217 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 430 435 430 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 490 496 490 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 89 94 <span type="species:ncbi:9606">human</span>
###xml 226 231 <span type="species:ncbi:9606">human</span>
###xml 446 453 <span type="species:ncbi:9606">patient</span>
###xml 569 574 <span type="species:ncbi:9606">human</span>
In breast cancer, ISG15 expression has so far only been examined in benign and malignant human breast cell lines [13]. To the best of our knowledge, this is the first study to systematically analyse the expression of ISG15 in human breast carcinomas and normal breast tissues both at the mRNA and the protein level. We analysed the results particularly in correlation to clinicopathological data, such as hormone receptor status, HER2 status and patient survival data, in order to validate ISG15 as a new prognostic marker and potential drug target in the treatment of human breast cancer.
###end p 15
###begin title 16
Materials and methods
###end title 16
###begin p 17
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 860 862 860 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
###xml 393 401 <span type="species:ncbi:9606">patients</span>
###xml 504 512 <span type="species:ncbi:9606">patients</span>
###xml 978 986 <span type="species:ncbi:9606">patients</span>
ISG15 protein expression was assessed in two independent cohorts of breast cancer patients using tissue microarrays (TMAs). The first tumour cohort has been previously described [17] and consisted of 179 breast cancer tissue specimens and 51 normal breast tissue specimens. The TMA used one tissue core from non-selected, formalin-fixed, paraffin-embedded primary breast cancer specimens from patients diagnosed between 1994 and 2002 at the Institute of Pathology, University of Regensburg, Germany. The patients' ages ranged from 25 to 82 years with a median age of 56 years. An experienced surgical pathologist (AH) evaluated slides of all specimens, stained with haematoxylin and eosin (H&E), before construction of the TMA in order to identify representative tumour areas. Histologically, all tumours were graded according to criteria by Elston and Ellis [18]. Clinical follow-up data, provided by the German Central Tumour Registry were available for all 179 breast cancer patients with a median follow-up period of 78 months (range 0 to 148 months). The Institutional Review Board of the participating centres approved the study.
###end p 17
###begin p 18
###xml 498 500 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 501 503 501 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 223 231 <span type="species:ncbi:9606">patients</span>
###xml 241 253 <span type="species:ncbi:9606">participants</span>
###xml 658 666 <span type="species:ncbi:9606">patients</span>
###xml 954 962 <span type="species:ncbi:9606">patients</span>
The second TMA for validation consisted of 967 breast specimens, of which it was possible to analyse 646 breast carcinomas and 10 normal breast tissues samples. The second TMA was constructed from a cohort of breast cancer patients who were participants of a case-controlled trial for the assessment of breast cancer susceptibility markers and prognostic factors, the Bavarian Breast Cancer Cases and Controls (BBCC), which has been described previously, including methods for the data collection [19,20]. The database for this analysis closed on 31 December, 2007 and had a median follow up of 4.7 years. Paraffin embedded tissue was available for 967 BBCC patients. Briefly a 0.6 mm punch was retrieved from the breast cancer tumour after a pathologist (AD) evaluated H&E-stained slides of all specimens. Data about the hormone receptor status were obtained from original pathological reports of these specimens; the other data were collected from the patients' medical records.
###end p 18
###begin p 19
###xml 63 64 63 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 85 88 85 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(n </italic>
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
The collection of paraffin-embedded and formalin-fixed normal (n = 14) and cancerous (n = 25) breast tissue samples for the mRNA expression analysis has been described previously [21].
###end p 19
###begin title 20
Cell lines
###end title 20
###begin p 21
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human mammary epithelial cell lines HMEC and MCF12A, and the breast cancer cell lines MCF7, T47D, ZR75-1, MDA-MB231, MDA-MB468, SKBR3 and BT20 were obtained from the ATCC (Rockville, MD, USA) and cultured as previously described [22].
###end p 21
###begin title 22
RNA extraction and reverse transcription
###end title 22
###begin p 23
###xml 509 511 507 509 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
Total RNA was isolated using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's recommendations. For paraffin-embedded tissues, five consecutive sections (each 5 mum thick) were prepared, deparaffinised and conventionally re-hydrated in a decreasing alcohol-series before RNA extraction. Of the obtained RNA, 1 mug was reverse transcribed using the Reverse Transcription System (Promega, Madison, WI, USA). In order to improve the transcription rate oligo-dT was mixed with pdN6 primers at a ratio of 1:2.
###end p 23
###begin title 24
Semiquantitative real-time PCR
###end title 24
###begin p 25
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 295 301 295 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 392 398 392 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
Semiquantitative PCR was performed using the LightCycler system with the LightCycler DNA Master SYBR Green I Kit (Roche Diagnostics, Mannheim, Germany) as previously described [22]. To ensure the accuracy of the experiment, all reactions were performed in triplicate. Primer sequences used were:ISG15 sense 5'- GAG AGG CAG CGA ACT CAT CT -3' and antisense 5'- CTT CAG CTC TGA CAC CGA CA -3'; GAPDH sense 5'- GAA GGT GAA GGT CGG AGT CA -3' and antisense 5'- AAT GAA GGG CTC ATT GAT GG -3'. The annealing temperature for both genes was 60degreesC. Reaction specificity was controlled by post-amplification melting curve analyses and gel electrophoresis of the obtained products.
###end p 25
###begin title 26
Breast cancer cDNA dot-blot hybridisation
###end title 26
###begin p 27
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 324 326 324 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 178 186 <span type="species:ncbi:9606">patients</span>
The breast cancer profiling array (BD Clontech, Heidelberg, Germany) contains 50 pairs of cDNAs generated from matched tumourous and normal breast tissue samples from individual patients and three breast cancer lymph node metastasis specimens, spotted on a nylon membrane [23]. Hybridisations using 25 ng of a gene-specific 32P-labelled cDNA probe digested from Unigene cDNA clones were conducted according to the manufacturer's recommendations. The tumour/normal intensity ratio was calculated using a STORM-860 phosphoimager (Molecular Dynamics, Sunnyvale, CA, USA) and normalised against the background.
###end p 27
###begin p 28
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 385 390 385 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 874 879 874 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 1070 1072 1070 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
Immunohistochemical studies for the expression of HER2 utilised an avidin-biotin peroxidase method with a 3,3'-diaminobenzidine chromatogen. After antigen retrieval (microwave oven for 30 minutes at 200W) immunohistochemistry studies were performed in a NEXES immunostainer (Ventana, Tucson, AZ, USA) according to the manufacturer's instructions. The primary antibodies used were anti-HER2 (DAKO, Hamburg, Germany; 1:400), anti-oestrogen receptor (ER) and anti-progesterone receptor (PR) (Novocastra, Newcastle Upon Tyne, UK; 1:20). For target proteins, the ChemMate detection kit (DAKO, Hamburg, Germany) was used. A surgical pathologist (AH) performed a blinded evaluation of the TMA slides with no knowledge of clinical data. It was not possible to interpret some results for reasons that included a lack of tumour tissue and the presence of necrosis or crush artefacts. HER2 expression was scored according to the DAKO HercepTest. For the evaluation of the presence of ER and PR, a semiquantitative immunoreactivity score (IRS), as described by Remmele and Stegner [24], was used.
###end p 28
###begin title 29
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
ISG15 Immunohistochemistry
###end title 29
###begin p 30
###xml 558 564 558 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 1059 1061 1059 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 575 581 <span type="species:ncbi:9986">rabbit</span>
The TMAs of both the evaluation set and the validation set were subjected to immunostaining using the Advance Kit (K4068, DAKO, Hamburg, Germany) following the manufacturer's instructions. Paraffin-embedded breast carcinomas were used as positive controls. After deparaffinisation and rehydration the tissue samples were heated in a microwave oven for 30 minutes at 200W in 10 mM sodium citrate buffer (pH 7.2). Endogenous peroxidase was blocked by peroxidase-blocking solution (S2023, DAKO, Hamburg, Germany) for 10 minutes. The polyclonal primary antibody ISG15 (AP 1150a, rabbit, Abgent, San Diego, CA, USA) was applied (1:30 dilution) for 30 minutes at room temperature. The primary antibody was omitted in the negative controls. For signal detection 3,3'-diaminobenzidine was used. Slides were counterstained with H&E and after dehydration mounted in Vitro-Clud (Langenbrinck, Emmendingen, Germany). Two experienced pathologists (NB, AN) scored the immunohistochemical staining intensity according to the scoring system suggested by Remmele and Stegner [24].
###end p 30
###begin title 31
Statistical methods
###end title 31
###begin p 32
###xml 193 194 193 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 412 413 412 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
For statistical evaluation SPSS version 14.0 (SPSS Inc, Chicago, IL) was used. Differences were considered statistically significant when p < 0.05. A non-parametrically two-tailed Mann-Whitney U-test was employed to analyse differences in expression levels. For analysis of the cancer profiling array, a Kolmogorov-Smirnov test was applied to test for a normal value distribution, followed by a two-sided paired t-test to analyse differences in normal and tumour expression. A statistical association between clinicopathological and molecular parameters was tested for using a two-sided Fisher's exact test. Recurrence-free survival (RFS) and overall survival (OS) were calculated according to the Kaplan-Meier equation.
###end p 32
###begin p 33
###xml 352 358 352 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 325 333 <span type="species:ncbi:9606">patients</span>
For the BBCC-TMA, RFS was defined as any local recurrence or distant recurrence, whatever occurred first. Event-free survival (EFS) was defined as any local recurrence, distant recurrence or death, whatever occurred first. Kaplan-Meier estimates were used to display the survival curves and log-rank test was used to compare patients with high vs. low ISG15 expression. For multivariate analyses, a Cox proportional hazard model was constructed for OS, EFS and RFS.
###end p 33
###begin title 34
Results
###end title 34
###begin title 35
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 25 30 <span type="species:ncbi:9606">human</span>
Upregulation of ISG15 in human breast cancer cell lines
###end title 35
###begin p 36
###xml 51 57 51 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 168 174 168 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 269 275 269 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 473 479 473 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 492 493 492 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 520 526 520 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 701 703 701 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 725 726 725 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 104 109 <span type="species:ncbi:9606">human</span>
We started the study by investigating the level of ISG15 mRNA expression in non-malignant and malignant human mammary cell lines. Real-time PCR analysis revealed a low ISG15 mRNA expression among the non-malignant mammary epithelial cell lines HMEC and MCF12A, whereas ISG15 mRNA transcript levels varied more and in summary were clearly elevated in the cancerous cell lines BT20, MDA-MB468, MDA-MB231, T47D and MCF7, of which MCF7 displayed an exceptionally high level of ISG15 mRNA (Figure 1). The median elevation of ISG15 expression in malignant cell lines vs. non-malignant cell lines was 2.5-fold and these differences in expression between the respective groups were statistically significant (p = 0.043, Mann-Whitney U-test). Differences in expression levels between ER-positive and ER-negative breast cancer cell lines were statistically not significant.
###end p 36
###begin p 37
###xml 31 37 31 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 119 125 119 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 248 254 248 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 357 363 357 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
Abundance of the expression of ISG15 mRNA in breast cancer cell lines. Semiquantitative real-time PCR (LightCycler) of ISG15 expression was performed on reverse transcribed RNA from non-malignant (white bars) and malignant cell lines (black bars). ISG15 mRNA expression was low among the non-malignant mammary epithelial cell lines HMEC and MCF12A, whereas ISG15 mRNA transcript levels varied more and in summary were elevated in the investigated cancerous cell lines.
###end p 37
###begin title 38
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
Upregulation of ISG15 in primary breast cancers analysed by real-time PCR
###end title 38
###begin p 39
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 66 67 66 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 102 103 102 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 223 229 223 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 354 355 354 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 384 390 384 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 539 541 539 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 563 564 563 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
Next we analysed ISG15 mRNA expression in primary breast cancers (n = 25) and normal mammary samples (n = 14) derived from formalin-fixed, paraffin-embedded tissues by real-time PCR. In line with our breast cell line data, ISG15 mRNA was abundantly expressed in primary breast cancer specimens when compared with normal mammary epithelial tissue (Figure 2). The median fold change of ISG15 upregulation in the cancerous tissue vs. normal tissue was 10.3 and differences in expression between the two groups were statistically significant (p = 0.002, Mann-Whitney U-test).
###end p 39
###begin p 40
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 109 110 109 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 147 148 147 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 172 178 172 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 222 228 222 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
Upregulation of ISG15 mRNA in primary breast cancer. A collection of paraffin-embedded breast carcinomas (T; n = 25) and normal breast tissues (N; n = 14) was analysed for ISG15 expression by semiquantative real-time PCR. ISG15 was strongly upregulated at the transcript level in the tumourous tissues compared with the normal breast tissues.
###end p 40
###begin title 41
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
Correlation between ISG15 mRNA expression and protein expression
###end title 41
###begin p 42
###xml 296 302 296 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 424 426 424 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 448 449 448 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 542 548 542 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 619 625 619 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 693 699 693 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 885 886 885 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 901 902 901 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
We additionally analysed 10 paraffin-embedded breast carcinomas and corresponding normal breast tissues by both semiquantitative real-time PCR and immunohistochemistry in order to correlate mRNA and protein levels in the same tumour samples as well as in the corresponding normal breast tissues. ISG15 mRNA was significantly upregulated in breast cancer specimens when compared with the corresponding normal breast tissues (p = 0.003, Mann-Whitney U-test). The median change in the tumour was three-fold compared with normal breast tissue on ISG15 mRNA level. At the protein level as determined by immunohistochemistry ISG15 was overexpressed in the tumour and correlated with upregulation of ISG15 mRNA. The median IRS in the tumour was five compared with an IRS of two in normal breast tissue and differences between the groups were statistically significant (p < 0.01, Mann-Whitney U-test) (Figure 3).
###end p 42
###begin p 43
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 123 124 123 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 175 176 175 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 200 206 200 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 297 303 297 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 337 343 337 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
Correlation between ISG15 mRNA and protein expression. An additional collection of paraffin-embedded breast carcinomas (T; n = 10) and corresponding normal breast tissues (N; n = 10) was analysed for ISG15 expression by semiquantitative real-time PCR and immunohistochemistry in the same samples. ISG15 mRNA upregulation correlated with ISG15 protein expression in the same tumour sample (T) compared with the corresponding normal breast tissue (N). Magnification: 400x.
###end p 43
###begin title 44
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
Upregulation of ISG15 in primary breast cancer analysed by cDNA dot-blot hybridisation
###end title 44
###begin p 45
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 172 173 172 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 246 252 244 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 406 407 404 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 414 416 412 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
ISG15 upregulation was validated by dot-blot analysis on a nylon array containing spotted cDNAs derived from 50 matched pairs of normal and cancerous breast tissue (Figure 4). The cancer profiling array showed upregulation (fold change >/= 2) of ISG15 in 33 of 50 primary breast tumours (66%), as well as in one of three metastatic lymph nodes, compared with matched normal breast tissue (two-sided paired t-test: p < 0.001). Mean densitometric intensity in normal tissues was 1533 arbitrary units (standard deviation [SD] +/- 995) and 3571 arbitrary units (SD +/- 2292) in tumour tissues.
###end p 45
###begin p 46
###xml 274 280 274 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
Expression profiles were determined using cDNA dot-blot hybridisation analysis (BD Clontech) containing cDNA pairs derived from 50 matched normal breast tissues (N), tumourous breast tissues (T) and three lymph node metastastic tissues (marked with arrows). Upregulation of ISG15 was observed in primary breast tumours and in one of three metastatic lymph nodes, as compared with matched normal breast tissue.
###end p 46
###begin title 47
###xml 18 24 18 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
Overexpression of ISG15 protein in primary breast carcinomas
###end title 47
###begin p 48
###xml 100 106 100 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 378 384 378 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 428 433 428 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a, b</xref>
###xml 456 464 456 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 472 477 472 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5c, d</xref>
###xml 479 485 479 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 581 586 581 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5e, f</xref>
###xml 601 607 601 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 678 686 678 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 748 753 748 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5g, h</xref>
###xml 883 889 883 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
Two independent cohorts of breast cancer specimens arranged on two different TMAs were analysed for ISG15 expression by immunohistochemistry. These represented an initial evaluation set, consisting of 179 breast carcinomas and 51 normal breast tissues, and an independent validation set, consisting of 646 breast carcinomas and 10 normal breast tissues. In normal breast tissue ISG15 expression was often absent or weak (Figure 5a, b). In ductal carcinoma in situ (Figure 5c, d) ISG15 expression was more intense than in normal breast tissue. In invasive breast carcinomas (Figure 5e, f, ductal type) ISG15 expression was generally more abundant than in either ductal carcinoma in situ or normal breast tissue. In tubular breast carcinomas (Figure 5g, h), a less frequent variant of invasive breast carcinomas with a more favourable prognosis than invasive ductal breast carcinomas, ISG15 expression was less abundant than in most invasive ductal breast carcinomas.
###end p 48
###begin p 49
###xml 34 40 34 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 174 180 174 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 229 243 229 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ ISG15 </italic>
###xml 367 373 367 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 508 515 508 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 691 697 691 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
Immunohistochemical expression of ISG15 in normal breast tissue, and in non-invasive and invasive breast tumours using a tissue microarray. (a, b) Normal breast tissue lacks ISG15 expression (IRS = 0). (c, d) In ductal carcinoma in situ ISG15 expression is more intense (IRS = 8) than in normal breast tissue. (e, f) In invasive breast carcinomas (here: ductal type) ISG15 expression was clearly more abundant (example shows staining with an IRS = 12) compared with normal breast tissue and ductal carcinoma in situ. (g, h) In tubular breast carcinomas (IRS = 4), a less frequent variant of invasive breast carcinomas with a more favourable prognosis than invasive ductal breast carcinomas, ISG15 expression was less abundant than in most invasive ductal breast carcinomas and stronger than in most normal breast tissues. Magnifications: a, c, e, g: 100x; b, d, f, h: 400x.
###end p 49
###begin title 50
Statistical analysis of the initial evaluation TMA cohort
###end title 50
###begin p 51
###xml 77 78 77 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 80 81 80 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 83 84 83 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
###xml 86 87 86 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S4">4</xref>
###xml 116 122 116 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 207 209 207 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 343 344 343 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
###xml 383 389 383 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 536 542 536 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 667 669 667 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 695 696 695 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 714 715 714 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S4">4</xref>
###xml 747 753 747 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 934 940 934 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 1002 1008 1002 1008 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 1103 1109 1103 1109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 1137 1138 1137 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 1156 1157 1156 1157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S4">4</xref>
###xml 1215 1221 1215 1221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 718 726 <span type="species:ncbi:9606">Patients</span>
###xml 906 914 <span type="species:ncbi:9606">patients</span>
###xml 1082 1090 <span type="species:ncbi:9606">patients</span>
Statistical data of the initial TMA cohort are presented in Additional files 1, 2, 3, 4. In the initial TMA cohort, ISG15 protein expression in breast carcinomas (IRS > 4) was associated with the ER status (p = 0.028), but not with tumour size, lymph node status, histological grading, focality or histological type of tumour (Additional file 3). To investigate a possible impact of ISG15 overexpression on clinical outcome we calculated univariate survival probability curves with respect to immunohistochemical results. We found that ISG15 expression in breast cancer (IRS > 4) showed an unfavourable prognosis with regard to RFS as shown by Kaplan-Meier analysis (p = 0.012) (Additional file 1, Additional file 4). Patients who showed abundant ISG15 expression in the tumour had an estimated mean RFS of 112 months (95% confidence interval [CI]: 99 to 125) compared with 78 months (95% CI: 68 to 87) in patients with negative/weak ISG15 expression. Although OS was not significantly associated with ISG15 overexpression, there was a trend towards unfavourable prognosis in those patients with strong ISG15 expression (Additional file 2, Additional file 4). Possibly due to a weak association with the ER status, ISG15 expression could not be identified as an independent prognostic factor in a multivariate analysis in this breast cancer cohort.
###end p 51
###begin title 52
Validation in the Bavarian breast cancer cases and controls tissue microarray cohort
###end title 52
###begin p 53
###xml 282 283 282 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 348 349 348 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 388 394 388 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 464 470 464 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 568 570 568 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 794 800 794 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 826 828 826 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 844 850 844 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 877 878 877 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 966 972 966 972 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 1000 1006 1000 1006 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 1118 1119 1118 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1132 1133 1132 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 1138 1139 1138 1139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 1222 1228 1222 1228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 1279 1280 1279 1280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
To confirm our results from the initial evaluation set of tumours, we analysed a second larger cohort (from BBCC) of breast cancer specimens on a TMA. In this validation cohort the IRS score was available for 646 invasive breast cancer cases. The mean IRS score was 3.5 with 83.9% (n = 542) of tumours having a low score of zero to four and 16.1% (n = 104) showing abundant expression of ISG15 (IRS > 4). As in the initial set we found a close association between ISG15 expression and an unfavourable prognosis (that is hazard ratio (HR) = 1.94; 95% CI: 1.17 to 3.23; p = 0.01 in OS analysis). However, this cohort of tumours was divided into two groups of similar size for efficient correlation analysis. Therefore, the validation set of the additional 646 breast tumours was divided into low ISG15 expressers (IRS = 0 to 3; n = 333) and high ISG15 expressers (IRS = 4 to 12; n = 313). Under this slightly different cut-off level (IRS > 3), the prognostic value of ISG15 expression was improved, as ISG15 immunohistochemical expression was also an independent predictor for OS and EFS in multivariate analysis (Table 1 and Figures 6 and 7). Furthermore, under this cut-off level, clear associations could be seen between ISG15 expression and both tumour size and grading (Table 2).
###end p 53
###begin p 54
Cox proportional hazard ratio analysis of the validation set (variables were categorised as indicated in Table 2)
###end p 54
###begin p 55
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 86 89 86 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
aAccording to Sobin LH, Wittekind CH: UICC: TNM Classification of Malignant Tumours. 6th edition, New York: Wiley; 2002. [36]. CI, Confidence interval
###end p 55
###begin p 56
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
Association of ISG15 immunoreactivity with clinical and pathological characteristics assessed in clinical routine examination of the validation set
###end p 56
###begin p 57
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 86 89 86 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
aAccording to Sobin LH, Wittekind CH: UICC: TNM Classification of Malignant Tumours. 6th edition, New York: Wiley; 2002 [36]. SD, Standard deviation; n/a, not available; pT, Pathological assessment of the primary tumour; pN, Pathological assessment of the regional lymph nodes.
###end p 57
###begin p 58
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 139 145 139 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 203 205 203 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 36 43 <span type="species:ncbi:9606">patient</span>
###xml 115 123 <span type="species:ncbi:9606">patients</span>
Correlation of ISG15 expression and patient prognosis according to univariate Kaplan-Meier analysis. Breast cancer patients overexpressing ISG15 show unfavourable prognosis in overall survival analysis (p = 0.001).
###end p 58
###begin p 59
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 139 145 139 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 200 202 200 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 36 43 <span type="species:ncbi:9606">patient</span>
###xml 115 123 <span type="species:ncbi:9606">patients</span>
Correlation of ISG15 expression and patient prognosis according to univariate Kaplan-Meier analysis. Breast cancer patients overexpressing ISG15 exhibit unfavourable prognosis in event-free survival (p = 0.001).
###end p 59
###begin title 60
Discussion
###end title 60
###begin p 61
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 171 177 171 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 223 229 223 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 381 387 381 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 503 509 503 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 639 641 639 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 697 699 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 764 770 764 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 871 877 871 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 1088 1094 1088 1094 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 1220 1222 1220 1222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1277 1283 1277 1283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 419 424 <span type="species:ncbi:9606">human</span>
###xml 531 536 <span type="species:ncbi:9606">human</span>
###xml 1206 1211 <span type="species:ncbi:10090">mouse</span>
ISG15 is a type I interferon regulated gene that is induced as a primary response to diverse microbial and cell stress stimuli [10]. Although the biological activities of ISG15 have yet to be elucidated, it is thought that ISG15 plays an important role in host defence and stress response pathways that have antitumour functions [10]. Consistent with this view, alterations in the ISG15 pathway have been identified in human tumours and in tumour cell lines. Increased expression of free and conjugated ISG15 has been exhibited in human breast, ovarian, prostate, colorectal and melanoma tumour cell lines compared with normal cell lines [13]. In accordance with the work of Desai and colleagues [13], who analysed two cell lines and showed abundant expression of ISG15 in the breast cancer cell line ZR-75-1 but not in the BT474 cell line, we also found upregulation of ISG15 mRNA in several additional breast cancer cell lines analysed (that is, BT20, MDA-MB468, MDA-MB231, T47D and MCF7) when compared with the benign mammary cell lines HMEC and MCF12A. Interestingly, upregulation of ISG15 was highly abundant in the breast cancer cell line MDA-MB231, a cell line shown to be highly metastatic in nude mouse models [25]. This could implicate a possible association between ISG15 upregulation and enhanced proliferation or invasiveness of cancer cells.
###end p 61
###begin p 62
###xml 34 40 34 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 176 182 176 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 330 336 330 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 469 475 469 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 117 122 <span type="species:ncbi:9606">human</span>
###xml 339 344 <span type="species:ncbi:9606">human</span>
###xml 489 494 <span type="species:ncbi:9606">human</span>
###xml 734 741 <span type="species:ncbi:9606">patient</span>
In agreement with the findings of ISG15 upregulation in diverse tumour cell lines in culture, microarray analyses of human tumour biopsies have revealed enhanced expression of ISG15 in pancreatic adenocarcinoma [14], endometrial cancer [13] and bladder cancer [12], when compared with the respective normal tissues. Expression of ISG15 in human cancerous and normal breast tissue has not been previously analysed. In the current study, a systematic characterisation of ISG15 expression in human breast cancer cells is presented for the first time at both the mRNA and the protein level, and includes a large cohort of breast carcinoma specimens that have been analysed by correlative analysis using clinicopathological parameters and patient survival data.
###end p 62
###begin p 63
###xml 61 63 61 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 64 66 64 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 93 99 93 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 197 203 197 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 287 293 287 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 397 403 397 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 509 510 509 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 561 567 561 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 611 613 611 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 653 659 653 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 747 748 747 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 814 820 814 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 883 885 883 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 899 901 899 901 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 927 929 927 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 993 999 993 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 1117 1123 1117 1123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 1319 1321 1319 1321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1322 1324 1322 1324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1348 1350 1348 1350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1473 1481 1473 1481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1774 1780 1774 1780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 1874 1880 1874 1880 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 2038 2040 2038 2040 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 2043 2049 2043 2049 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 2210 2212 2210 2212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 2213 2215 2213 2215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 2228 2234 2228 2234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 40 45 <span type="species:ncbi:9606">human</span>
###xml 442 449 <span type="species:ncbi:9606">patient</span>
###xml 800 808 <span type="species:ncbi:9606">patients</span>
###xml 970 978 <span type="species:ncbi:9606">patients</span>
###xml 1087 1095 <span type="species:ncbi:9606">patients</span>
###xml 1361 1365 <span type="species:ncbi:10090">mice</span>
###xml 1371 1376 <span type="species:ncbi:9606">human</span>
###xml 1828 1833 <span type="species:ncbi:9606">human</span>
###xml 2117 2122 <span type="species:ncbi:9606">human</span>
In accordance with previous findings in human cancer tissue [12-14] we found upregulation of ISG15 at the mRNA level in breast carcinomas compared with normal breast tissue. Enhanced expression of ISG15 in breast cancer was further validated by cDNA dot-blot analysis. Overexpression of ISG15 protein in breast carcinomas could be confirmed by immunohistochemistry of a TMA. Using this technique, ISG15 protein expression was correlated with patient survival data. In the initial cohort of breast carcinomas (n = 179) we found a significant correlation between ISG15 expression and unfavourable prognosis (RFS; p = 0.012) suggesting a potential role of ISG15 in breast cancer development. Analysis of the second, independent breast cancer cohort (n = 967) confirmed this. I0n the validation TMA set, patients with ISG15 overexpression (IRS > 3) showed unfavourable prognosis in RFS (p = 0.03), EFS (p = 0.001) and OS analyses (p = 0.001). This unfavourable prognosis of patients with abundant ISG15 expression might be due to an insufficient response to chemotherapy in this subgroup of patients. Indeed, deregulated ISG15 expression has been found in response to diverse cancer chemotherapeutic agents, such as paclitaxel in the treatment of ovarian carcinomas and 5-fluorouracil in the therapy of oesophageal cancer [26,27]. Bani and colleagues [26] analysed mice with human ovarian carcinoma xenografts undergoing treatment with paclitaxel as a way of understanding the in vivo molecular consequences of drug treatment. By analysing expression changes by cDNA microarray they found that paclitaxel could affect the level of expression of a variety of genes in those ovarian tumours responding to treatment. So the expression of several interferon-inducible genes such as ISG15 was reduced in the responders. Surprisingly, in human oesophageal squamous cancer cell lines, ISG15 was found to be upregulated after treatment with the chemotherapeutic agent 5-fluorouracil as shown by DNA microarray analysis and reverse transcription-PCR [27]. ISG15 mRNA expression was also found to be upregulated after treatment of human colorectal and breast cancer cell lines with campothecin, a topoisomerase I inhibitor [28,29]. Therefore ISG15 may be regulated differentially in response to different chemotherapeutic regimens.
###end p 63
###begin p 64
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 86 88 86 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 113 114 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
###xml 152 154 152 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 169 170 169 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 338 343 338 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15</italic>
###xml 383 385 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 534 536 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 782 784 782 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 785 787 785 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 906 908 906 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1187 1195 1179 1187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">de novo </italic>
###xml 1496 1498 1480 1482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1499 1501 1483 1485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1711 1717 1695 1701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 1014 1022 <span type="species:ncbi:9606">patients</span>
Interestingly, ISG15 expression was associated with ER status in the initial TMA set (p = 0.028; Additional file 3), but not in the validation TMA set (p = 0.177, Table 2), as oestrogen is known to play a modulatory role in the ISGylation pathway. Indeed the ligating (E3) enzyme, that is a part of the post-translational modification by ISG15, was shown to be oestrogen-responsive [30]. The so-called ISGylation is mediated by a multi-step pathway, comprised of activating (E1), conjugating (E2) and ligating (E3) enzyme components [30]. The oestrogen responsiveness of the ligating (E3) enzyme in the ISGylation pathway is of great importance because ERs play a major role in the regulation of growth, survival and differentiation of normal and malignant breast epithelial cells [31,32]. Therefore, the determination of breast tumour hormone receptor status is of major importance for therapy selection [33]. Approximately 60 to 80% of all breast cancers abundantly express ERalpha, but only two-thirds of those patients are responsive to endocrinal treatment (anti-oestrogen therapy). Intriguingly, a proportion of ERalpha-positive tumours do not respond to hormone treatment at all (de novo resistance) while the majority of those tumours that initially responded to anti-oestrogens eventually become resistant during treatment (acquired resistance). Most ER-resistant tumours remain ERalpha-positive, suggesting a continued role for ERalpha in breast cancer cell survival and proliferation [34,35]. The likely development of ER-resistance during breast cancer treatment with anti-oestrogens emphasises the urgent need for surrogate target molecules that may be able to bypass these resistances. Therefore, ISG15 might be a target molecule in the therapy of drug-resistant breast tumours.
###end p 64
###begin title 65
Conclusion
###end title 65
###begin p 66
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 146 152 146 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 226 232 226 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 390 396 390 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 610 616 610 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 732 738 732 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 893 898 893 898 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15</italic>
###xml 44 49 <span type="species:ncbi:9606">human</span>
###xml 190 195 <span type="species:ncbi:9606">human</span>
Our analyses showed ISG15 overexpression in human breast carcinomas relative to normal breast tissue at the RNA and protein level indicating that ISG15 may represent a candidate oncogene in human breast cancer. Interestingly, ISG15 could function as a novel breast tumour marker with prognostic or predictive significance. Recently, microarray experiments determined strong deregulation of ISG15 expression in response to diverse cancer chemotherapeutic agents, for example, paclitaxel in the treatment of ovarian carcinomas or 5-fluorouracil in the therapy of oesophageal cancer. These findings indicate that ISG15 could represent a predictive biomarker in the treatment of these cancers as well. However, the putative function of ISG15 in breast carcinogenesis and in chemotherapeutic response has to be further analysed in prospective studies. As a next step we will investigate whether an ISG15-based diagnostic assay is able to predict response to specific chemotherapy regimens in the treatment of breast cancer.
###end p 66
###begin title 67
Abbreviations
###end title 67
###begin p 68
###xml 162 167 162 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15</italic>
BBCC = Bavarian Breast Cancer Cases and Controls; EFS = Event-free survival; ER = Oestrogen receptor; H&E = Haematoxylin and eosin; IRS = Immunoreactivity Score; ISG15 = Interferon-stimulated gene 15 kDa; OS = Overall survival; PCR = polymerase chain reaction; RFS = Recurrence-free survival; TMA = Tissue microarray.
###end p 68
###begin title 69
Competing interests
###end title 69
###begin p 70
The authors declare that they have no competing interests.
###end p 70
###begin title 71
Authors' contributions
###end title 71
###begin p 72
NB: participated in the design of the study, data analysis, data interpretation, establishment and evaluation of the immunohistochemistry and drafted the manuscript; EN: carried out the immunohistochemical studies, and critically revised the manuscript; JV: supported with expertise in molecular biology techniques and in data interpretation and critically revised the manuscript; MFP: participated in construction of the BBCC-TMA and data analysis; GK: supported in data interpretation and critically revised the manuscript; AN: participated in the evaluation and interpretation of the immunohistochemical data; AH: supported in data interpretation and critically revised the manuscript; AD: did the histological review for all tumours included in the TMA and participated in TMA construction and data analyses, and critically revised the manuscript; MWB: supported in data interpretation and critically revised the manuscript; RK: participated in design and coordination of the study, and critically revised the manuscript; PAF: participated in construction of the BBCC-TMA, study design and coordination, data analysis, data interpretation and drafting of the manuscript; ED: conceived the study, participated in the study design and coordination, molecular and data analysis, data interpretation and drafting of the manuscript.
###end p 72
###begin p 73
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 139 145 139 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 214 216 214 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 36 43 <span type="species:ncbi:9606">patient</span>
###xml 115 123 <span type="species:ncbi:9606">patients</span>
Correlation of ISG15 expression and patient prognosis according to univariate Kaplan-Meier analysis. Breast cancer patients overexpressing ISG15 have an unfavourable prognosis in recurrence-free survival analysis (p = 0.030).
###end p 73
###begin title 74
Supplementary Material
###end title 74
###begin title 75
Additional file 1
###end title 75
###begin p 76
###xml 39 45 39 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 182 188 182 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 260 262 260 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 60 67 <span type="species:ncbi:9606">patient</span>
###xml 162 170 <span type="species:ncbi:9606">patients</span>
Tif file that shows the correlation of ISG15 expression and patient prognosis according to univariate Kaplan-Meier analysis in the initial TMA set. Breast cancer patients expressing ISG15 exhibit an unfavourable prognosis in recurrence-free survival analysis (p = 0.012).
###end p 76
###begin p 77
Click here for file
###end p 77
###begin title 78
Additional file 2
###end title 78
###begin p 79
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 178 184 178 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
###xml 258 260 258 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 56 63 <span type="species:ncbi:9606">patient</span>
###xml 158 166 <span type="species:ncbi:9606">patients</span>
Tif file that shows correlation of ISG15 expression and patient prognosis according to univariate Kaplan-Meier analysis in the initial TMA set. Breast cancer patients expressing ISG15 show a trend towards unfavourable prognosis in overall survival analysis (p = 0.128).
###end p 79
###begin p 80
Click here for file
###end p 80
###begin title 81
Additional file 3
###end title 81
###begin p 82
###xml 114 120 114 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
Word file containing a table presenting the clinicopathological and immunohistochemical parameters in relation to ISG15 immunoreactivity in the initial TMA set.
###end p 82
###begin p 83
Click here for file
###end p 83
###begin title 84
Additional file 4
###end title 84
###begin p 85
Word file containing a table presenting the univariate analysis of factors regarding overall survival (OS) and recurrence-free survival (RFS) in the initial TMA set.
###end p 85
###begin p 86
Click here for file
###end p 86
###begin title 87
Acknowledgements
###end title 87
###begin p 88
###xml 183 188 <span type="species:ncbi:9606">Human</span>
The technical assistance of Inge Losen and Sonja von Serenyi is greatly appreciated. The study was supported by the German Ministry for Education and Research as a part of the German Human Genome Project to PD Dr. Edgar Dahl and by a grant (START program) of the Faculty of Medicine, RWTH Aachen, to Dr. Nuran Bektas. We thank Ivonne Villalobos and Armen Gasparyan very much for their dedicated help constructing the BBCC-TMA.
###end p 88
###begin article-title 89
The interferon-inducible 15-kDa ubiquitin homolog conjugates to intracellular proteins
###end article-title 89
###begin article-title 90
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15</italic>
ISG15, not just another ubiquitin-like protein
###end article-title 90
###begin article-title 91
Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays
###end article-title 91
###begin article-title 92
Interferon induces a 15-kilodalton protein exhibiting marked homology to ubiquitin
###end article-title 92
###begin article-title 93
Serpin 2a is induced in activated macrophages and conjugates to a ubiquitin homolog
###end article-title 93
###begin article-title 94
###xml 55 60 55 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15</italic>
High-throughput immunoblotting. Ubiquitin-like protein ISG15 modifies key regulators of signal transduction
###end article-title 94
###begin article-title 95
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15</italic>
###xml 60 65 <span type="species:ncbi:10090">mouse</span>
###xml 70 75 <span type="species:ncbi:9606">human</span>
Proteomic identification of proteins conjugated to ISG15 in mouse and human cells
###end article-title 95
###begin article-title 96
###xml 6 11 6 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways
###end article-title 96
###begin article-title 97
Immunity by ubiquitylation: a reversible process of modification
###end article-title 97
###begin article-title 98
###xml 49 54 49 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15</italic>
The interferon regulated ubiquitin-like protein, ISG15, in tumorigenesis: friend or foe?
###end article-title 98
###begin article-title 99
A model for p53-induced apoptosis
###end article-title 99
###begin article-title 100
###xml 63 68 63 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15</italic>
Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer
###end article-title 100
###begin article-title 101
###xml 23 29 23 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15 </italic>
Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway
###end article-title 101
###begin article-title 102
Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays
###end article-title 102
###begin article-title 103
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15</italic>
Viral defense, carcinogenesis and ISG15: novel roles for an old ISG
###end article-title 103
###begin article-title 104
Pre-mRNA splicing: awash in a sea of proteins
###end article-title 104
###begin article-title 105
Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer
###end article-title 105
###begin article-title 106
Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up
###end article-title 106
###begin article-title 107
###xml 54 63 54 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(CYP19A1)</italic>
###xml 113 121 <span type="species:ncbi:9606">patients</span>
Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients
###end article-title 107
###begin article-title 108
Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer
###end article-title 108
###begin article-title 109
Systematic characterisation of GABRP expression in sporadic breast cancer and normal breast tissue
###end article-title 109
###begin article-title 110
Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis
###end article-title 110
###begin article-title 111
Clontech/Information on the Cancer Profiling Array
###end article-title 111
###begin article-title 112
Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue
###end article-title 112
###begin article-title 113
Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231
###end article-title 113
###begin article-title 114
Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts
###end article-title 114
###begin article-title 115
5-Fluorouracil up-regulates interferon pathway gene expression in esophageal cancer cells
###end article-title 115
###begin article-title 116
###xml 49 54 49 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15</italic>
###xml 69 74 69 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ISG15</italic>
Camptothecin induces the ubiquitin-like protein, ISG15, and enhances ISG15 conjugation in response to interferon
###end article-title 116
###begin article-title 117
Ubiquitin, SUMO-1, and UCRP in camptothecin sensitivity and resistance
###end article-title 117
###begin article-title 118
Epigenetic and proteolytic inactivation of 14-3-3sigma in breast and prostate cancers
###end article-title 118
###begin article-title 119
Estrogen receptor expression in benign breast epithelium and breast cancer risk
###end article-title 119
###begin article-title 120
Estrogen and progesterone receptors in the normal female breast
###end article-title 120
###begin article-title 121
Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches
###end article-title 121
###begin article-title 122
Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates
###end article-title 122
###begin article-title 123
Effects of endocrine therapy on steroid-receptor content of breast cancer
###end article-title 123

